| 1. |
- Schrijver, L, et al.
(författare)
-
Oral contraceptive use and breast cancer risk: A cohort study of BRCA1 and BRCA2 mutation carriers
- 2017
-
Ingår i: Cancer Research. - 1538-7445. ; 77:13 Suppl 1
-
Konferensbidrag (refereegranskat)abstract
- Background: BRCA1 and BRCA2 mutation carriers are at high risk of breast and ovarian cancer. Oral contraceptive preparations (OCPs) may reduce ovarian cancer risk, but its effect on breast cancer risk remains unclear. Methods: Combined data from three cohorts of 5705 BRCA1 and 3521 BRCA2 mutation carriers (IBCCS, BCFR and kConFab) were analyzed using age-dependent Cox regression models stratified for study and birth cohort. We conducted the first prospective analyses on this topic. Our additional main retrospective analyses were leftcensored 5 years preceding date of baseline questionnaire to control for survival bias. The full-cohort retrospective analyses, without left-censoring, was performed to compare results with the literature. Prospective analyses were considered most valid, while retrospective analyses were most powerful. Results: For BRCA1 mutation carriers we found no association between ever OCP use and risk of breast cancer in the prospective analyses (HR=1.08, 95% CI 0.75-1.56), but 23% and 27% increased risks for ever OCP use in the left-censored and full retrospective analyses, respectively. Retrospectively, an increasing trend for longer duration of use, especially before first full-term pregnancy (FFTP) was found (left-censored analyses: 10 years HR 1.41 (95%CI 1.10-1.813), p-trend=0.001 for duration of use before FFTP). For BRCA2 mutation carriers we found a positive association between ever OCP use and risk of breast cancer prospectively (HR=1.75, 95% CI 1.03-2.97), but retrospectively findings were inconsistent (HR=1.06, 95% CI 0.85-1.33 and HR=1.52, 95% CI 1.28-1.81 for the left-censored and full analyses, respectively). Conclusion: For BRCA1 mutation carriers the discrepancy between results of prospective and retrospective analyses may be explained by time since last OCP use before FFTP. Thus, a temporal increased risk of breast cancer following longer duration of OCP use before FFTP cannot be ruled out. The discordant findings between prospective and retrospective analyses for BRCA2 carriers could not be explained. Because of the lack of scientific clarity it is too early to give an unequivocal advice on OCP use with respect to breast cancer risk to BRCA1 and BRCA2 mutation carriers.
|
|
| 2. |
- Belitsky, Victor, 1955, et al.
(författare)
-
ALMA Band 2 Cold Cartridge Assembly Design
- 2022
-
Ingår i: 32nd International Symposium of Space Terahertz Technology, ISSTT 2022.
-
Konferensbidrag (refereegranskat)abstract
- As part of the ALMA development, we present the design of the ALMA Band 2 Cold Cartridge Assembly (CCA). The Band 2 is the last band that completes the suit of the 10 receiver channels of ALMA. The originally planned ALMA Band 2 receiver cartridge should cover the RF band of 67 - -90 GHz. The recent progress in technology, optics, OMT design and mm-wave amplifiers, however allowed to implement receiver that has an extended RF band up to 116 GHz. Furthermore, the Band 2 receiver pursues 2SB layout and provides 4-18 GHz IF band for two sidebands in a dual-polarization configuration. Here, we describe the design of the Band 2 CCA that includes optics, amplifier assembly, internal RF transport, mechanics and cryogenics. The downconverter part and performances are described elsewhere.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Krischbaum, T.T., et al.
(författare)
-
Towards the event horizon - the vicinity of AGN at micro-arcsecond resolution
- 2004
-
Ingår i: in "Proceedings of the 7th European VLBI Network Symposium", Oct. 2004, Toledo, eds. R. Bachiller, F. Colomer, J.F. Desmurs, P. de Vicente, Obs. Astronómico Nacional, Alcala de Henares, Spain. ; , s. 15-18
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
